SMAD2 and pulmonary arterial hypertension: These ligands, like TGF-β isoforms, activate SMAD2/3 signaling and might therefore act in concert with TGF-β, exerting pathogenic effects through overlapping or distinct mechanisms during pathologic vascular remodeling in PAH.